← Back to Search

Reminder System for Osteoporosis Care

N/A

Waitlist Available

Led By William D Leslie, MD MSc

Research Sponsored by University of Manitoba

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Women and men age 50 and older with a humerus fracture (physician ICD-9-CM code 812)

Women and men age 50 and older with a hip fracture (physician ICD-9-CM 820-821 plus a procedure code for site-specific fracture reduction or fixation, open or closed)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years (phase 1 analysis at 1 year)

Awards & highlights

Study Summary

This trial is testing a notification system to remind physicians and patients of the importance of osteoporosis care after a fracture.

Who is the study for?

This trial is for men and women aged 50 or older in Manitoba who have recently had specific fractures (humerus, spine, hip with procedure, Colles' with procedure or cast) indicating possible osteoporosis. Excluded are non-residents, those under age 50, recent fracture patients, current osteoporosis medication users, and those with recent BMD tests.Check my eligibility

What is being tested?

The study aims to improve post-fracture care by testing a notification system that alerts physicians and/or patients about fractures that suggest underlying osteoporosis. The goal is to enhance bone mineral density testing and treatment after such fractures.See study design

What are the potential side effects?

Since the intervention involves information letters rather than medications or medical procedures, there are no direct physical side effects expected from participating in this clinical trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 50 or older and have a broken upper arm.

Select...

I am 50 or older and have had a hip fracture treated.

Select...

I am 50 or older and have had a spine fracture.

Select...

I am 50 or older and have had a specific type of wrist fracture treated.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years (phase 1 analysis at 1 year)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years (phase 1 analysis at 1 year)

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years (phase 1 analysis at 1 year) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rates of BMD testing and/or osteoporosis pharmacotherapy in the year post-fracture using the population-based provincial administrative health data repository.

Secondary outcome measures

An evaluation of post-fracture BMD testing and treatment rates in the years prior to the Phase 1 will also be performed to document practice patterns before the intervention.

For individuals referred for BMD testing, an evaluation of treatment appropriateness will be performed based upon BMD results and 10-year fracture risk methods.

Repeat fracture rates will be also studied as a secondary endpoint.